# ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

> **NCT03769506** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Rakuten Medical, Inc.** · enrollment: 135 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **COMBINATION_PRODUCT:** ASP-1929 Photoimmunotherapy
- **DRUG:** Physician's Choice SOC

## Key facts

- **NCT ID:** NCT03769506
- **Lead sponsor:** Rakuten Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-09
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03769506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03769506, "ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03769506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*